Richtlijn HIV
Deze pagina is het laatst bewerkt op 9 nov 2023 om 17:48. | Deze pagina is 58.089 maal bekeken.

Lijst met verwijzingen naar andere richtlijnen

Uit Richtlijnen HIV

(Verschil tussen bewerkingen)
Ga naar: navigatie, zoeken
(47 tussenliggende versies worden niet weergegeven)
Regel 1: Regel 1:
-
In onderstaande tabel staan verwijzingen naar andere richtlijnen opgesomd:  
+
In onderstaande tabel staan per hoofdstuk/paragraaf verwijzingen naar andere richtlijnen vermeld:<br>
-
<br>  
+
{| width="100%" border="1" align="left" cellspacing="1" cellpadding="1"
 +
|-
 +
| valign="top" align="left" | '''Pagina'''<br>  
 +
| width="45" valign="top" align="left" | '''Link naar andere richtlijn'''
 +
|-
 +
| valign="top" align="left" | [[Inhoud|'''Inhoud''']]
 +
| width="45" valign="top" align="left" | SOA richtlijn<br>PrEP richtlijn
 +
|-
 +
| valign="top" align="left" | '''[[Hoofdstuk 2. Therapie bij volwassenen]]<br>'''
 +
| width="45" valign="top" align="left" | <br>
 +
|-
 +
| valign="top" align="left" | [[2.1. Wanneer beginnen?]] <br>
 +
| width="45" valign="top" align="left" | DHHS
 +
|-
 +
| valign="top" align="left" | [[2.2. Keuze van antiretrovirale therapie bij naïeve volwassenen met hiv|2.2. Keuze van anti-retrovirale therapie bij naïeve volwassenen met hiv]]<br>
 +
| width="45" valign="top" align="left" | DHHS
 +
|-
 +
| valign="top" align="left" | [[2.3. Tijdelijk onderbreken van antiretrovirale therapie|2.3. Tijdelijk onderbreken van anti-retrovirale therapie]]<br>
 +
| width="45" valign="top" align="left" | DHHS
 +
|-
 +
| valign="top" align="left" | [[2.4. Richtlijn anti-retrovirale therapie bij voorbehandelde mensen met hiv|2.4. Richtlijn anti-retrovirale therapie bij voorbehandelde mensen met hiv]]<br>
 +
| width="45" valign="top" align="left" | DHHS
 +
|-
 +
| valign="top" align="left" | '''[[Hoofdstuk 3. Behandeling van hiv-1 infectie bij kinderen|Hoofdstuk 3. Behandeling van hiv-1 infectie bij kinderen]]'''
 +
| width="45" valign="top" align="left" | DHHS<br>Kinderformularium
 +
|-
 +
| valign="top" align="left" | '''[[Hoofdstuk 4. Monitoring]]<br>'''
 +
| width="45" valign="top" align="left" | DHHS
 +
|-
 +
| valign="top" align="left" | [[4.2. Spiegelbepaling]]<br>
 +
| width="45" valign="top" align="left" |
 +
DHHS<br>EACS<br>TDM-protocollen
-
{| width="100%" cellspacing="0" cellpadding="0" border="1" style="mso-yfti-irow:0;mso-yfti-firstrow:yes" class="MsoTableGrid"
 
|-
|-
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
| valign="top" align="left" | [[4.3. Resistentiebepalingen]]<br>  
-
'''Pagina'''
+
| width="45" valign="top" align="left" | DHHS
-
 
+
|-
-
| width="269" valign="top" style="width:201.9pt;border:solid windowtext 1.0pt; border-left:none;mso-border-left-alt:solid windowtext .5pt;mso-border-alt: solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
| valign="top" align="left" | '''[[Hoofdstuk 5. Diagnostiek en behandeling primaire hiv-infectie|Hoofdstuk 5. Diagnostiek en behandeling primaire hiv-infectie]]<br>'''  
-
'''Verwijzing naar andere richtlijnen'''
+
| width="45" valign="top" align="left" | DHHS
-
 
+
|-
-
|- style="mso-yfti-irow:1"
+
| valign="top" align="left" | '''[[Hoofdstuk 7. Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale periode]]<br>'''  
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
| width="45" valign="top" align="left" | DHHS&nbsp;<br> Landelijk hiv expositie protocol neonaten
-
'''&lt;a'''
+
|-
-
 
+
| valign="top" align="left" | '''[[Hoofdstuk 8. HIV-2 bij volwassenen: Behandeling en monitoring]]<br>'''  
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Richtlijn%20HIV"&gt;Hoofdpagina''' '''(=inhoudsopgave)&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
| width="45" valign="top" align="left" | DHHS
-
 
+
|-
-
<br>
+
| valign="top" align="left" | '''[[Hoofdstuk 9. Bijzondere omstandigheden]]'''  
-
 
+
| width="45" valign="top" align="left" |  
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
|-
-
<span style="mso-bidi-font-weight:bold">
+
| valign="top" align="left" | [[9.5. Adviezen m.b.t. gebruik anti-hiv middelen door de sonde]]
-
</span>
+
| width="45" valign="top" align="left" | EACS
-
 
+
|-
-
|- style="mso-yfti-irow:2"
+
| valign="top" align="left" | [[9.6. Doseringen bij gestoorde leverfunctie]]
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
| width="45" valign="top" align="left" | EACS
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
|-
-
 
+
| valign="top" align="left" | [[9.7. Doseringen bij gestoorde nierfunctie]]
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
| width="45" valign="top" align="left" | EACS
-
<span style="mso-bidi-font-weight:bold">
+
|-
-
</span>
+
| valign="top" align="left" | '''[[Hoofdstuk 10. Behandeling van hepatitis B/C-virus coïnfectie bij mensen met hiv-1|Hoofdstuk 10. Behandeling van hepatitis B/C-virus coïnfectie bij mensen met hiv-1]]<br>'''  
-
 
+
| width="45" valign="top" align="left" | <br>
-
|- style="mso-yfti-irow:3"
+
|-
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
| valign="top" align="left" | [[10.1. Hepatitis B]]<br>  
-
'''&lt;a'''
+
| width="45" valign="top" align="left" | HBV richtsnoer<br>DHHS<br>EACS
-
 
+
|-
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%201.%20Achtergrondinformatie%20bij%20de%20ontwikkeling%20en%20herziening%20van%20deze%20richtlijn%20en%20inleiding"&gt;Hoofdstuk 1. Achtergrondinformatie bij de ontwikkeling en herziening van deze richtlijn''' '''en inleiding&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
| valign="top" align="left" | [[10.2. Hepatitis C|10.2. Hepatitis C]]
-
 
+
| width="45" valign="top" align="left" | HCV richtsnoer<br> DHHS<br>EACS
-
<br>  
+
|-
-
 
+
| valign="top" align="left" | [[10.3. HCC surveillance|10.3. HCC surveillance]]
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
| width="45" valign="top" align="left" | HBV richtsnoer
-
<span style="mso-bidi-font-weight:bold">NVHB Richtlijn 2007</span>
+
|-
-
 
+
| valign="top" align="left" | '''[[Hoofdstuk 11. Behandeling van tuberculose bij mensen met een hiv-infectie|Hoofdstuk 11. Behandeling van tuberculose bij mensen met een hiv-infectie]]<br>'''  
-
|- style="mso-yfti-irow:4"
+
| width="45" valign="top" align="left" | KNCV
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
|-
-
&lt;a
+
| valign="top" align="left" | '''[[Hoofdstuk 12. Comorbiditeit en bijwerkingen]]<br>'''  
-
 
+
| width="45" valign="top" align="left" | EACS<br>
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Procedure%20herziening"&gt;Procedure herziening&lt;/a&gt;
+
|-
-
 
+
| valign="top" align="left" | '''[[Hoofdstuk 13. Screening van mensen met hiv op anogenitale maligniteiten|Hoofdstuk 13. Screening van mensen met hiv op anogenitale maligniteiten]] <br>'''
-
<br>
+
| width="45" valign="top" align="left" | DHHS<br> CIN cervicale intra-epitheliale neoplasie
-
 
+
|-
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
| valign="top" align="left" | '''[[Hoofdstuk 14. Interacties]]'''  
-
NVHB Richtlijn 2007
+
| width="45" valign="top" align="left" | EACS
-
 
+
|-
-
|- style="mso-yfti-irow:5"
+
| valign="top" align="left" | [[Hoofdstuk 15. Profylaxe en behandeling van opportunistische infectie|'''Hoofdstuk 15. Profylaxe en behandeling van opportunistische infectie''']]
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
| width="45" valign="top" align="left" | DHHS<br>Nationale Antibioticaboekje<br>SWAB richtlijnen
-
&lt;a
+
|-
-
 
+
| valign="top" align="left" | '''[[Hoofdstuk 16. Transmissiemanagement]]<br>'''  
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Samenstelling%20kernwerkgroep"&gt;Samenstelling kernwerkgroep&lt;/a&gt;
+
| width="45" valign="top" align="left" | <br>
-
 
+
|-
-
<br>
+
| valign="top" align="left" | [[16.1. Prikaccidenten]]<br>  
-
 
+
| width="45" valign="top" align="left" | LCI
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
|-
-
<br>
+
| valign="top" align="left" | [[16.2. Seksaccidenten]]<br>  
-
 
+
| width="45" valign="top" align="left" | LCI/RIVM
-
|- style="mso-yfti-irow:6"
+
|-
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
| valign="top" align="left" | '''[[Hoofdstuk 17. Vaccinatiebeleid]]<br>'''  
-
&lt;a
+
| width="45" valign="top" align="left" | <br>
-
 
+
|-
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Overzicht%20belangen%20werkgroepleden"&gt;Overzicht belangen werkgroepleden&lt;/a&gt;
+
| valign="top" align="left" | [[17.2. Vaccinatie tegen influenza]] <br>  
-
 
+
| width="45" valign="top" align="left" | RIVM<br>NHG
-
<br>
+
|-
-
 
+
| valign="top" align="left" | [[17.4. Vaccinaties tegen Hepatitis A en B]]<br>  
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
| width="45" valign="top" align="left" | RIVM
-
|- style="mso-yfti-irow:7"
+
|-
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
| valign="top" align="left" | [https://richtlijnhiv.nvhb.nl/index.php/Addendum:%C2%A0SOA-richtlijn '''Addendum:''' SOA-richtlijn]
-
&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Definities"&gt;Definities&lt;/a&gt;
+
| width="45" valign="top" align="left" | SOA richtlijn
-
 
+
|-
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
| valign="top" align="left" | [http://richtlijnhiv.nvhb.nl/images/2/22/PrEP-richtlijn-Nederland-8-september-2016-met-logos.pdf '''Addendum:'''&nbsp;Pre-exposure profylaxe (PrEP) richtlijn]
-
<br>
+
| width="45" valign="top" align="left" | PrEP-richtlijn
-
 
+
-
|- style="mso-yfti-irow:8"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
Geschiedenis per pagina van deze richtlijn (= huidige pagina)
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:9"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:10"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%202.%20Therapie%20bij%20volwassenen"&gt;Hoofdstuk''' '''2. Therapie bij volwassenen&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:11"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.1.%20Wanneer%20beginnen?"&gt;2.1. Wanneer beginnen?&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:12"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20wanneer%20starten"&gt;Onderbouwing wanneer starten&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
+
-
 
+
-
|- style="mso-yfti-irow:13"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%202.1"&gt;Literatuur 2.1&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:14"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.2.%20Keuze%20van%20antiretrovirale%20therapie%20bij%20na%C3%AFeve%20volwassen%20pati%C3%ABnten"&gt;2.2. Keuze van antiretrovirale therapie bij naïeve volwassen patiënten&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
+
-
 
+
-
|- style="mso-yfti-irow:15"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%202.2"&gt;Literatuur 2.2&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:16"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.3.%20Tijdelijk%20onderbreken%20van%20HAART"&gt;2.3. Tijdelijk onderbreken van HAART&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
+
-
 
+
-
|- style="mso-yfti-irow:17"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/T%C2%BD%20van%20antiretrovirale%20middelen"&gt;T½ van antiretrovirale middelen&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:18"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/2.4.%20Richtlijn%20anti-retrovirale%20therapie%20bij%20voorbehandelde%20pati%C3%ABnten"&gt;2.4. Richtlijn <span class="SpellE">anti-retrovirale</span> therapie bij <span class="SpellE">voorbehandelde</span> patiënten&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span class="SpellE"><span class="GramE">Aidsinfo</span></span> NIH
+
-
 
+
-
|- style="mso-yfti-irow:19"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:20"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%203.%20Behandeling%20van%20HIV-1%20infectie%20bij%20kinderen"&gt;Hoofdstuk''' '''3. Behandeling van HIV-1 infectie bij kinderen&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:21"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:22"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%204.%20Monitoring"&gt;Hoofdstuk''' '''4. Monitoring&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:23"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/4.1.%20Controles%20HIV-pati%C3%ABnten%20%28polikliniek%29"&gt;4.1. Controles HIV-patiënten (polikliniek)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:24"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Bij%20eerste%20consult%20bij%20HIV-seropositieve%20pati%C3%ABnt%20%28polikliniek%29"&gt;Bij eerste consult bij <span class="SpellE">HIV-seropositieve</span> patiënt (polikliniek)&lt;/a&gt;&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Bij%20instellen%20op%20antiretrovirale%20therapie%20%28polikliniek%29" _fcknotitle=true _fcksavedurl="Bij instellen op antiretrovirale therapie (polikliniek)"&gt;Bij instellen op antiretrovirale therapie (polikliniek)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:25"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Eerste%20controle%20na%20instellen%20op%20anti-retrovirale%20therapie%204-6%20weken%20na%20start%20%28polikliniek%29"&gt;Eerste controle na instellen op <span class="SpellE">anti-retrovirale</span> therapie 4-6 weken na start (polikliniek)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:26"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Controle%20van%20pati%C3%ABnten%20op%20antiretrovirale%20therapie%20%28polikliniek%29"&gt;Controle van patiënten op antiretrovirale therapie (polikliniek)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:27"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Controle%20van%20pati%C3%ABnten%20zonder%20antiretrovirale%20therapie%20%28polikliniek%29"&gt;Controle van patiënten zonder antiretrovirale therapie (polikliniek)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:28"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/4.2.%20Spiegelbepaling"&gt;4.2. Spiegelbepaling&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:29"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/4.3.%20Resistentiebepalingen"&gt;4.3. Resistentiebepalingen&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:30"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:31"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%205.%20Diagnostiek%20en%20behandeling%20primaire%20HIV-infectie"&gt;Hoofdstuk''' '''5. Diagnostiek en behandeling primaire <span class="SpellE">HIV-infectie</span>&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:32"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:33"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%206.%20Therapietrouw%20bevorderende%20maatregelen"&gt;Hoofdstuk''' '''6. Therapietrouw bevorderende maatregelen&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:34"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/6.1.%20Therapietrouw%20be%C3%AFnvloedende%20factoren"&gt;6.1. Therapietrouw beïnvloedende factoren&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:35"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%206.1"&gt;Literatuur 6.1&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:36"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/6.2.%20Therapietrouw%20bevorderende%20interventies"&gt;6.2. Therapietrouw bevorderende interventies&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:37"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20therapietrouw%20bevorderende%20interventies"&gt;Onderbouwing therapietrouw bevorderende interventies&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:38"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%206.2"&gt;Literatuur 6.2&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:39"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:40"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%207.%20Preventie%20van%20moeder-kind%20overdracht:%20zwangerschap,%20bevalling%20en%20neonatale%20periode"&gt;Hoofdstuk 7. Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale''' '''periode&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
<span class="SpellE"><span class="GramE"><span style="mso-bidi-font-weight: bold">Aidsinfo</span></span></span><span style="mso-bidi-font-weight:bold">
+
-
NIH Perinatal</span>
+
-
 
+
-
<span style="mso-bidi-font-weight:bold">NVHB Richtlijn 2007</span>
+
-
 
+
-
|- style="mso-yfti-irow:41"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%207"&gt;Literatuur 7&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:42"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:43"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%208.%20HIV-2%20bij%20volwassenen:%20Behandeling%20en%20monitoring"&gt;Hoofdstuk''' '''8. HIV-2 bij volwassenen: Behandeling en monitoring&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<span class="SpellE"><span class="GramE"><span style="mso-bidi-font-weight: bold">Aidsinfo</span></span></span><span style="mso-bidi-font-weight:bold">
+
-
NIH</span>
+
-
 
+
-
|- style="mso-yfti-irow:44"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%208"&gt;Literatuur 8&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:45"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:46"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%209.%20Bijzondere%20omstandigheden"&gt;Hoofdstuk''' '''9. Bijzondere omstandigheden&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:47"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.1.%20Adviezen%20m.b.t.%20inname%20van%20anti-HIV%20middelen%20na%20braken"&gt;9.1. Adviezen m.b.t. inname van anti-HIV middelen na braken&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:48"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.2.%20Adviezen%20m.b.t.%20inname%20van%20anti-HIV%20middelen%20bij%20vergeten%20van%20slikmoment"&gt;9.2. Adviezen m.b.t. inname van anti-HIV middelen bij vergeten van slikmoment&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:49"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.3.%20Marge%20tussen%20twee%20innames"&gt;9.3. Marge tussen twee innames&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:50"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.4.%20Inname%20medicatie%20bij%20overschrijden%20tijdzones"&gt;9.4. Inname medicatie bij overschrijden tijdzones&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:51"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.5.%20Adviezen%20m.b.t.%20gebruik%20anti-HIV%20middelen%20door%20de%20sonde"&gt;9.5. Adviezen m.b.t. gebruik anti-HIV middelen door de sonde&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:52"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/9.6.%20Doseringen%20bij%20gestoorde%20lever-%20en%20nierfunctie"&gt;9.6. Doseringen bij gestoorde lever- en nierfunctie&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:53"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:54"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2010.%20Behandeling%20van%20hepatitis%20B/C-virus%20co%C3%AFnfectie%20bij%20HIV-1%20positieve%20pati%C3%ABnten"&gt;Hoofdstuk 10. Behandeling van hepatitis B/C-virus <span class="SpellE">coïnfectie</span>''' '''bij HIV-1 positieve patiënten&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:55"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/10.1.%20Hepatitis%20B"&gt;<span lang="EN-US" style="mso-ansi-language:EN-US">10.1. Hepatitis B</span>&lt;/a&gt;<span lang="EN-US" style="mso-ansi-language:EN-US">&lt;o:p&gt;&lt;/o:p&gt;</span>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
EACS  
+
-
 
+
-
|- style="mso-yfti-irow:56"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/10.2.%20Hepatitis%20C%C2%A0%28acuut%29"&gt;<span lang="EN-US" style="mso-ansi-language:EN-US">10.2. Hepatitis C&nbsp;(<span class="SpellE">acuut</span>)</span>&lt;/a&gt;<span lang="EN-US" style="mso-ansi-language: EN-US">&lt;o:p&gt;&lt;/o:p&gt;</span>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
NL aanbevelingen
+
-
 
+
-
NEAT
+
-
 
+
-
|- style="mso-yfti-irow:57"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Levels%20of%20evidence"&gt;<span lang="EN-US" style="mso-ansi-language:EN-US">Levels of evidence</span>&lt;/a&gt;<span lang="EN-US" style="mso-ansi-language:EN-US">&lt;o:p&gt;&lt;/o:p&gt;</span>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:58"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2010.2"&gt;Literatuur 10.2&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:59"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/10.3.%20Hepatitis%20C%C2%A0%28chronisch%29"&gt;10.3. Hepatitis C&nbsp;(chronisch)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
EACS
+
-
 
+
-
|- style="mso-yfti-irow:60"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
<br>
+
-
 
+
-
|- style="mso-yfti-irow:61"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2011.%20Behandeling%20van%20tuberculose%20bij%20pati%C3%ABnten%20met%20een%20HIV-infectie"&gt;Hoofdstuk''' '''11. Behandeling van tuberculose bij patiënten met een HIV-<span class="SpellE">infectie</span>&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:62"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2011"&gt;Literatuur 11&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:63"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:64"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2012.%20Comorbiditeit%20en%20bijwerkingen"&gt;Hoofdstuk''' '''12. Comorbiditeit en bijwerkingen&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
<span style="mso-bidi-font-weight:bold">EACS</span>  
+
-
 
+
-
|- style="mso-yfti-irow:65"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:66"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2013.%20Screening%20van%20HIV-pati%C3%ABnten%20op%20anogenitale%20maligniteiten"&gt;Hoofdstuk''' '''13. Screening van HIV-patiënten op anogenitale maligniteiten&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:67"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20screening%20van%20HIV-pati%C3%ABnten%20op%20anogenitale%20maligniteiten"&gt;Onderbouwing screening van HIV-patiënten op anogenitale maligniteiten&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:68"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2013"&gt;Literatuur 13&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:69"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:70"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2014.%20Interacties"&gt;Hoofdstuk''' '''14. Interacties&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:71"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:72"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2015.%20Profylaxe%20en%20behandeling%20van%20opportunistische%20infectie"&gt;Hoofdstuk''' '''15. Profylaxe en behandeling van opportunistische infectie&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:73"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:74"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
Hoofdstuk 16. Post Exposure Profylaxe na prikaccident en onveilig <span class="SpellE">sexueel</span> contact
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:75"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2016.%20Transmissiereductie%20%28PEP%29"&gt;Hoofdstuk''' '''16. <span class="GramE">Transmissiereductie</span> (PEP)&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:76"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/16.1.%20Prikaccidenten"&gt;16.1. Prikaccidenten&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
LCI  
+
-
 
+
-
|- style="mso-yfti-irow:77"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/16.2.%20Seksaccidenten"&gt;16.2. Seksaccidenten&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
LCI/RIVM  
+
-
 
+
-
|- style="mso-yfti-irow:78"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:79"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2017.%20Vaccinatiebeleid"&gt;Hoofdstuk''' '''17. Vaccinatiebeleid&lt;/a&gt;&lt;o:p&gt;&lt;/o:p&gt;'''  
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:80"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.1.%20Vaccinaties%20bij%20HIV-ge%C3%AFnfecteerde%20kinderen"&gt;17.1. Vaccinaties bij <span class="SpellE">HIV-geïnfecteerde</span> kinderen&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
CDC
+
-
 
+
-
|- style="mso-yfti-irow:81"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.2.%20Vaccinatie%20tegen%20influenza"&gt;17.2. Vaccinatie tegen influenza&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
NHG Standaard
+
-
 
+
-
|- style="mso-yfti-irow:82"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20Vaccinatie%20tegen%20influenza"&gt;Onderbouwing Vaccinatie tegen influenza&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:83"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2017.2"&gt;Literatuur 17.2&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:84"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.3.%20Vaccinatie%20tegen%20infecties%20met%20Streptococcus%20pneumoniae%20%28Pneumokokken%29"&gt;17.3. Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:85"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Onderbouwing%20Vaccinatie%20tegen%20infecties%20met%20Streptococcus%20pneumoniae%20%28Pneumokokken%29%20%28Pneumokokken%29"&gt;Onderbouwing Vaccinatie tegen infecties met Streptococcus pneumoniae (Pneumokokken) (Pneumokokken)&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:86"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Literatuur%2017.3"&gt;Literatuur 17.3&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:87"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.4.%20Vaccinaties%20tegen%20Hepatitis%20A%20en%20B"&gt;17.4. Vaccinaties tegen Hepatitis A en B&lt;/a&gt;
+
-
 
+
-
<br>  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
|- style="mso-yfti-irow:88"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a
+
-
 
+
-
href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/17.5.%20Vaccinatie%20bij%20HIV-ge%C3%AFnfecteerde%20reizigers"&gt;17.5. Vaccinatie bij <span class="SpellE">HIV-geïnfecteerde</span><span class="SpellE">reizigers</span>&lt;/a&gt;
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
LCR
+
-
 
+
-
CDC
+
-
 
+
-
|- style="mso-yfti-irow:89"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
&lt;a href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Bureau%27s%20voor%20reizigersadvisering"&gt;<span class="SpellE">Bureau's</span> voor reizigersadvisering&lt;/a&gt;
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:90"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |
+
-
'''&lt;o:p&gt;&nbsp;&lt;/o:p&gt;'''  
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
-
|- style="mso-yfti-irow:91;mso-yfti-lastrow:yes"
+
-
| width="350" valign="top" style="width:262.5pt;border:solid windowtext 1.0pt; border-top:none;mso-border-top-alt:solid windowtext .5pt;mso-border-alt:solid windowtext .5pt; padding:0cm 5.4pt 0cm 5.4pt" |  
+
-
'''&lt;a'''
+
-
 
+
-
'''href="http://www.nvhb.nl/richtlijnhiv/extensions/FCKeditor/fckeditor/editor/Hoofdstuk%2018.%20Kostenoverzicht%20antiretrovirale%20middelen"&gt;Hoofdstuk''' '''18. Kostenoverzicht antiretrovirale middelen&lt;/a&gt;'''
+
-
 
+
-
<br>
+
-
 
+
-
| width="269" valign="top" style="width:201.9pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; mso-border-top-alt:solid windowtext .5pt;mso-border-left-alt:solid windowtext .5pt; mso-border-alt:solid windowtext .5pt;padding:0cm 5.4pt 0cm 5.4pt" |
+
|}
|}
-
 
-
&lt;o:p&gt;&nbsp;&lt;/o:p&gt; &lt;/div&gt; &lt;/body&gt;&lt;/html&gt;
 

Versie op 28 apr 2021 12:32

In onderstaande tabel staan per hoofdstuk/paragraaf verwijzingen naar andere richtlijnen vermeld:

Pagina
 Link naar andere richtlijn
Inhoud SOA richtlijn
PrEP richtlijn
Hoofdstuk 2. Therapie bij volwassenen
2.1. Wanneer beginnen?
DHHS
2.2. Keuze van anti-retrovirale therapie bij naïeve volwassenen met hiv
 DHHS
2.3. Tijdelijk onderbreken van anti-retrovirale therapie
 DHHS
2.4. Richtlijn anti-retrovirale therapie bij voorbehandelde mensen met hiv
 DHHS
Hoofdstuk 3. Behandeling van hiv-1 infectie bij kinderen DHHS
Kinderformularium
Hoofdstuk 4. Monitoring
 		DHHS
4.2. Spiegelbepaling

DHHS
EACS
TDM-protocollen

4.3. Resistentiebepalingen
 DHHS
Hoofdstuk 5. Diagnostiek en behandeling primaire hiv-infectie
 		DHHS
Hoofdstuk 7. Preventie van moeder-kind overdracht: zwangerschap, bevalling en neonatale periode
 		DHHS 
Landelijk hiv expositie protocol neonaten
Hoofdstuk 8. HIV-2 bij volwassenen: Behandeling en monitoring
 		DHHS
Hoofdstuk 9. Bijzondere omstandigheden
9.5. Adviezen m.b.t. gebruik anti-hiv middelen door de sonde EACS
9.6. Doseringen bij gestoorde leverfunctie EACS
9.7. Doseringen bij gestoorde nierfunctie EACS
Hoofdstuk 10. Behandeling van hepatitis B/C-virus coïnfectie bij mensen met hiv-1
10.1. Hepatitis B
 HBV richtsnoer
DHHS
EACS
10.2. Hepatitis C HCV richtsnoer
DHHS
EACS
10.3. HCC surveillance HBV richtsnoer
Hoofdstuk 11. Behandeling van tuberculose bij mensen met een hiv-infectie
 		KNCV
Hoofdstuk 12. Comorbiditeit en bijwerkingen
 		EACS
Hoofdstuk 13. Screening van mensen met hiv op anogenitale maligniteiten
DHHS
CIN cervicale intra-epitheliale neoplasie
Hoofdstuk 14. Interacties EACS
Hoofdstuk 15. Profylaxe en behandeling van opportunistische infectie DHHS
Nationale Antibioticaboekje
SWAB richtlijnen
Hoofdstuk 16. Transmissiemanagement
16.1. Prikaccidenten
 LCI
16.2. Seksaccidenten
 LCI/RIVM
Hoofdstuk 17. Vaccinatiebeleid
17.2. Vaccinatie tegen influenza
RIVM
NHG
17.4. Vaccinaties tegen Hepatitis A en B
 RIVM
Addendum: SOA-richtlijn SOA richtlijn
Addendum: Pre-exposure profylaxe (PrEP) richtlijn PrEP-richtlijn
Teruggeplaatst van "https://richtlijnhiv.nvhb.nl/index.php/Lijst_met_verwijzingen_naar_andere_richtlijnen"